This activity allows companies to present their noteworthy new products and services through live presentations. Seating is available on a first-come, first-served basis. The Industry-Expert Theater content and views expressed therein are those of the companies and not of ASTRO.
Lunch or other food and beverages may be provided by the companies, which may subject you to reporting under the Federal Sunshine Act (the Open Payments Program) or other state laws. Otherwise, food may be available for purchase prior to the start of an event in the concessions area.
Friday, February 25, 2022
View the live streaming session.
DecisionDx-SCC: Use of a 40-gene expression profile to refine patient metastatic risk in head and neck cutaneous squamous cell carcinoma
Grand Canyon Ballroom 9 & 10
5:30 p.m. - 6:30 p.m. | Castle Biosciences
An in-depth review of cutaneous squamous cell carcinoma (cSCC) as an emerging problem in the U.S. with unmet clinical need for improved risk assessment. DecisionDx-SCC is a 40-gene expression profile test that predicts metastatic risk for cSCC patients with one or more risk factors. Integrating DecisionDx-SCC and clinicopathologic features for cSCC and cSCC-HN patients can inform management decisions within established guidelines.
Speaker: Andres M. Bur, MD, FACS, Associate Professor of Otolaryngology – Head and Neck Surgery, Director of Robotic and Minimally Invasive Head and Neck Surgery at the University of Kansas